دورية أكاديمية
Healthy cats tolerate long-term daily feeding of Cannabidiol.
| العنوان: | Healthy cats tolerate long-term daily feeding of Cannabidiol. |
|---|---|
| المؤلفون: | Coltherd JC; WALTHAM Petcare Science Institute, Waltham-on-the-Wolds, Melton Mowbray, United Kingdom., Bednall R; WALTHAM Petcare Science Institute, Waltham-on-the-Wolds, Melton Mowbray, United Kingdom., Bakke AM; WALTHAM Petcare Science Institute, Waltham-on-the-Wolds, Melton Mowbray, United Kingdom., Ellerby Z; WALTHAM Petcare Science Institute, Waltham-on-the-Wolds, Melton Mowbray, United Kingdom., Newman C; WALTHAM Petcare Science Institute, Waltham-on-the-Wolds, Melton Mowbray, United Kingdom., Watson P; WALTHAM Petcare Science Institute, Waltham-on-the-Wolds, Melton Mowbray, United Kingdom., Logan DW; WALTHAM Petcare Science Institute, Waltham-on-the-Wolds, Melton Mowbray, United Kingdom., Holcombe LJ; WALTHAM Petcare Science Institute, Waltham-on-the-Wolds, Melton Mowbray, United Kingdom. |
| المصدر: | Frontiers in veterinary science [Front Vet Sci] 2024 Jan 24; Vol. 10, pp. 1324622. Date of Electronic Publication: 2024 Jan 24 (Print Publication: 2023). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101666658 Publication Model: eCollection Cited Medium: Print ISSN: 2297-1769 (Print) Linking ISSN: 22971769 NLM ISO Abbreviation: Front Vet Sci Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Media S.A., [2014]- |
| مستخلص: | Cannabidiol (CBD)-containing products are widely commercially available for companion animals, mirroring popularity in human use. Although data on the safety and efficacy of long-term oral supplementation are increasing in dogs, evidence remains lacking in cats. The purpose of these studies was to address gaps in the knowledge around the long-term suitability and tolerance of a tetrahydrocannabinol (THC)-free CBD distillate in clinically healthy cats. The studies were randomized, blinded, and placebo-controlled. The first study supplemented cats with either a placebo oil ( n = 10) or with 4 mg/kg body weight (BW) CBD in placebo oil ( n = 9) daily, with a meal, for 4 weeks. The concentration of CBD in plasma was measured over 4 h at d0 (first dose) and again at d14 (after 2 weeks of daily dosing). The second study supplemented cats daily with either placebo oil ( n = 10) or 4 mg/kg BW CBD in placebo oil ( n = 10) for a period of 26 weeks. A comprehensive suite of physiological health measures was performed throughout the study at baseline (week 0) and after 4, 10, 18, and 26 weeks of feeding, followed by a 4-week washout sample (week 30). Postprandial plasma CBD time course data, at both d0 and d14, showed a peak plasma CBD concentration at 2 h after the dose. This peak was 251 (95% CI: 108.7, 393.4) and 431 (95% CI, 288.7, 573.4) ng/mL CBD at d0 and d14, respectively, and the area under the curve concentration was higher by 91.5 (95% CI, 33.1, 149.9) ng-h/mL after 2 weeks of supplementation ( p = 0.002). While in the first study the CBD group displayed increased alanine aminotransferase (ALT; 68.7 (95% CI, 43.23, 109.2) U/L) at week 4 compared to the placebo control group [1.44-fold increase (95% CI, 0.813, 2.54)], statistical equivalence (at 2-fold limits) was found for ALT across the duration of the second, long-term study. All other biochemistry and hematology data showed no clinically significant differences between supplement groups. Data presented here suggest that a THC-free, CBD distillate fed at a dose of 4 mg/kg BW was absorbed into plasma and well tolerated by healthy cats when supplemented over a period of 26 weeks. Competing Interests: JC, RB, AB, ZE, PW, DL, and LH are all employees of Mars Petcare, a manufacturer of pet food. CN was an employee of Mars Petcare during the completion of the trials detailed here. (Copyright © 2024 Coltherd, Bednall, Bakke, Ellerby, Newman, Watson, Logan and Holcombe.) |
| References: | Animals (Basel). 2022 Jan 31;12(3):. (PMID: 35158670) Animals (Basel). 2021 Mar 20;11(3):. (PMID: 33804793) Mo Med. 2018 Jul-Aug;115(4):306-309. (PMID: 30228748) Front Vet Sci. 2022 Sep 21;9:977457. (PMID: 36213402) Pharmacol Res. 2021 Feb;164:105357. (PMID: 33285233) Animals (Basel). 2019 Oct 19;9(10):. (PMID: 31635105) Biom J. 2008 Jun;50(3):346-63. (PMID: 18481363) Am J Vet Res. 2011 Apr;72(4):433-7. (PMID: 21453142) Vet Anaesth Analg. 2007 Jul;34(4):228-50. (PMID: 17451496) Curr Neuropharmacol. 2020;18(2):87-96. (PMID: 31481004) Sci Rep. 2021 Jul 22;11(1):14948. (PMID: 34294753) Pharmaceutics. 2022 Nov 25;14(12):. (PMID: 36559092) Am J Vet Res. 2023 Mar 29;84(5):. (PMID: 36972696) Nature. 1971 Aug 20;232(5312):579-80. (PMID: 4937510) CNS Drugs. 2020 Aug;34(8):795-800. (PMID: 32504461) Front Vet Sci. 2020 Feb 11;7:51. (PMID: 32118071) J Vet Intern Med. 2024 Jan-Feb;38(1):326-335. (PMID: 38009749) Res Vet Sci. 2021 Nov;140:38-46. (PMID: 34391060) EFSA J. 2022 Jun 07;20(6):e07322. (PMID: 35686177) Pain Manag. 2021 Apr;11(4):395-403. (PMID: 33703917) Front Vet Sci. 2023 May 26;10:1181517. (PMID: 37303724) J Feline Med Surg. 2019 Jan;21(1):12-24. (PMID: 30763154) Animals (Basel). 2022 Nov 24;12(23):. (PMID: 36496797) Front Vet Sci. 2022 Jul 22;9:895368. (PMID: 35937287) Nature. 2019 Aug;572(7771):S12-S13. (PMID: 31462791) Front Vet Sci. 2023 Feb 22;10:1112604. (PMID: 36908527) J Vet Pharmacol Ther. 2023 Jan;46(1):25-33. (PMID: 36300854) |
| فهرسة مساهمة: | Keywords: CBD; cannabidiol; cannabinoids; cat; feline; safety |
| تواريخ الأحداث: | Date Created: 20240208 Latest Revision: 20240210 |
| رمز التحديث: | 20240210 |
| مُعرف محوري في PubMed: | PMC10847353 |
| DOI: | 10.3389/fvets.2023.1324622 |
| PMID: | 38327816 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2297-1769 |
|---|---|
| DOI: | 10.3389/fvets.2023.1324622 |